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Background: Short-term oral immunotherapy (OIT) using the Cry j1-galactomannan conjugate for Jap-
anese cedar pollinosis may be effective and relatively safe. However, a treatment regimen has not been
established. In the present study, we examined a new OIT regimen with a build-up phase and extended
the maintenance phase of OIT to the peak period of the pollen season to enhance the therapeutic effect
and safety of OIT.
Methods: A prospective, randomized, open-label trial was conducted over a period of 4 months. Par-
ticipants were randomly divided into two groups. The OIT group comprised 23 subjects. The build-up
phase was initiated 1 month before the expected pollen season. The maintenance phase was
continued for 51 days during the peak pollen season. The control group comprised 24 subjects. The
symptoms and medication score, levels of allergen-speciﬁc serum antibodies throughout the pollen
season, and adverse effects with OIT were evaluated.
Results: Participants receiving OIT showed signiﬁcant improvements in total symptom scores, medica-
tion score, and total symptom-medication scores throughout the pollen season compared with the
control group. The levels of allergen-speciﬁc serum IgG4 were signiﬁcantly increased in the OIT group
but not in the control group throughout the cedar pollen season. Importantly, no severe adverse effects
were observed with OIT.
Conclusions: The new regimen of short-term OIT using the Cry j1-galactomannan conjugate for Japanese
cedar pollinosis is effective, relatively safe and induces immune tolerance. Thus, OIT using allergen
egalactomannan conjugates may provide a rapid, effective, and thus convenient immunotherapy for
pollinosis instead of SLIT or SCIT.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
In the past few decades, the prevalence of allergic disease has
been increasing in many developed country.1,2 In Japan, the prev-
alence of allergic rhinitis caused by Japanese cedar pollinosis (JCP)yngology, Graduate School of
1 Higashi-ku, Fukuoka 812-
(D. Murakami).
ety of Allergology.
rgology. Production and hosting by Elshas been increasing, and is currently around 25%.3 It is a signiﬁcant
health problem.4 To date, most subjects with JCP are treated with
antihistamines and corticosteroid nasal sprays to suppress allergic
symptoms. However, the effect of pharmacological treatment is
temporary. Therefore, long-term symptomatic control using
immunotherapy is desirable.
Subcutaneous immunotherapy (SCIT) is a curative treatment for
JCP. It is effective for allergic rhinitis and is supported by high-level
evidence that includes the results of meta-analyses.5 However, its
use in Japan has not become widespread because of various prob-
lems, including frequent medical visits for a few years, pain fromevier B.V. All rights reserved.
Fig. 1. Flow chart. Number of individuals assessed for the trial. Screening failures:
Participants who did not fulﬁll the inclusion criteria or met the exclusion criteria. AE,
Adverse events.
D. Murakami et al. / Allergology International 64 (2015) 161e168162injections, and the potential of severe side effects including
anaphylaxis. Just recently, sublingual immunotherapy (SLIT) for JCP
was approved by the Japanese Ministry of Health, Labour and
Welfare as a safe form of immunotherapy compared with SCIT.5,6
SLIT is expected to be a widely accepted treatment for JCP. How-
ever, SLIT also has some problems. A few years of treatment is
required before the therapeutic effect is apparent,7 so it takes
longer time before its therapeutic efﬁciency can be judged, and the
effect is thought to be somewhat weaker than SCIT.5 Therefore, the
development of an immunotherapy that is safe, effective and more
convenient with a shorter regimen is needed.
Oral immunotherapy (OIT) is a promising method for modu-
lating the immune response8e10 because many immune cells exist
in the mucosa of the digestive tract. In 1980s, the treatment of
pollinosis using OIT had been attempted.11e13 Although no severe
systemic side effects were reported, oral immunotherapy induced
many gastrointestinal adverse effects because the allergens were
administrated in their native form.13 In addition, the efﬁcacy of OIT
for pollinosis was controversial in the randomized control trials.14
Therefore, OIT for airway allergy including pollinosis is not
currently recommended byWorld Health Organization.15 However,
in recent years, the efﬁcacy of OIT for subjects with food allergy
including those allergic to cow's milk, peanuts, eggs, etc. has been
conﬁrmed.16e18 Thus, OIT for desensitization is in the spotlight
again as an effective treatment.
OIT has some advantages compared with SCIT and SLIT. Subjects
can ingest larger amounts of antigen each time and OIT is expected
to induce immune tolerance in a short time because a large number
of immune cells are present in the intestinal tract.19 However, it
would be helpful if gastrointestinal adverse effects and structural
failure of the antigen due to digestive enzymes in the stomach are
avoided. Therefore, the development of a new agent and regimen to
suppress adverse effects caused by the administered allergen in the
gut is desirable.
Cry j1 is a major allergen of JCP.20 In a previous study, we
demonstrated that a Cry j1-galactomannan conjugate could mask
the epitope sites of Cry j1, which completely inhibited the binding
of patient serum IgE to these allergens,21 and was trafﬁcked efﬁ-
ciently to dendritic cells in the gut lumen.22 These results suggest
that galactomannan binding to Cry j1 is effective at reducing the
risk of adverse effects and accelerate the uptake of antigen into gut
dendritic cells compared with Cry j1 alone. We have recently re-
ported that short-term OIT using the Cry j1-galactomannan con-
jugate for one month before the peak pollen season is effective and
relatively safe for JCP.23 However, the optimum regimen of OIT
using the Cry j1-galactomannan conjugate has not been established
and has been debated.
To enhance the therapeutic efﬁciency and safety of Cry j1-gal-
actomannan conjugate for JCP, we studied efﬁcacy (primary
outcome), safety and immune responses (secondary outcomes) of
the conjugate in a regimen that includes a build-up phase and
extension of the maintenance phase to peak pollen season.
Methods
Participants
This study was conducted in Kyushu University Hospital,
Fukuoka, Japan. Participants were recruited fromKyushu University
Hospital. Of 52 individuals who expressed interest for this study, 48
came to the clinic for screening (Fig. 1). The authors recruited
participants using the criteria described below. The study group
fulﬁlled the inclusion criteria and consisted of 48 Japanese partic-
ipants (27 men and 21 women), with an age range from 22 to 60
years, who were otherwise healthy but had moderate or severerhinoconjunctivitis due to JCP allergy. They had received pharma-
cological treatment for the last three consecutive cedar pollen
seasons, and lived in or around the city of Fukuoka in Japan, where a
similar amount of pollen spread was expected. The diagnosis of JCP
allergy was based on clinical history and serum Cry j1-speciﬁc IgE
levels associated with a score of 2 or greater using CAP-RAST (SRL
Inc., Tokyo, Japan). The exclusion criteria were as follows: severe
asthma, chronic sinusitis, previous immunotherapy or ongoing
immunotherapy with other allergens, treatment with b-blockers or
those on continuous corticosteroids, pregnancy or planned preg-
nancy, participation in another clinical trial, and other standard
contraindications for immunotherapy.24 Informed consent was
obtained from all participants. The study was conducted according
to the principles in the Declaration of Helsinki, and was approved
by the Institutional Ethics Committee of Kyushu University Hospital
(number 21082) and registered in UMIN-CTR (UMIN000013408).Study design
We performed a prospective, randomized, open-label study.
Participants were randomly divided into two groups: the OIT group
and the control group without OIT (but who could receive other
pharmacological treatment) using the envelope method. The OIT
group consisted of 23 Japanese participants (14 men and 9 women)
with an age range from 25 to 60 years. Onewoman in the OIT group
withdrew from the study for personal reasons before commence-
ment of OIT. The control group consisted of 24 Japanese partici-
pants (13 men and 11 women) with an age range from 22 to 58
years. The primary group for the analysis was the intention-to-treat
(ITT) group, deﬁned as all randomly assigned participants who
received at least one dose of the study medication, who recorded
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tion in an e-mail sent to the data center at least once.
In the OIT group in the build-up phase, the dose was gradually
increased to the maintenance dose over 18 days from the middle of
January 2012, one month before the JCP season. First, one capsule
(dose of Cry j1: 187.5 mg) of Cry j1-galactomannan conjugate was
administered orally after breakfast for 6 days. Second, a total of two
capsules daily (dose of Cry j1: 375 mg) of Cry j1-galactomannan
conjugate was administered orally i.e., one capsule after breakfast
and dinner, for 6 days. Third, three capsules daily (dose of Cry j1:
562.5 mg) of Cry j1-galactomannan conjugate were administered
orally after breakfast (two capsules) and dinner (one capsule) for 6
days. Afterward, the maintenance phase of OIT was started. Four
capsules (total dose of Cry j1: 750 mg) daily of Cry j1-
galactomannan conjugate, divided into two capsules twice a day,
were administered orally for 51 days from the beginning of
February 2012 to the end of March 2012 during the JCP season.
Participants in the control group did not undergo OIT and did not
receive placebo capsules. The physicians (who belonged to the
Nasal Allergy Study Group of the Department of Otorhinolaryn-
gology, Graduate School of Medical Sciences, Kyushu University)
examined the participants of both groups in Kyushu University
Hospital and checked the blood samples before the JCP season and
OIT (visit 1), at the beginning of the JCP season (visit 2), and after
the JCP season (visit 3) in both groups as shown in Fig. 2. The
participants received pharmacological treatment for rhino-
conjunctivitis due to JCP allergy throughout the JCP season ac-
cording to the Japanese Guidelines for Allergic Rhinitis.25 The
participants carefully recorded the mean score regarding their
nasal and ocular symptoms and the usage of rescue drugs (such as
antihistamines) per week in their pollen electronic ﬁle diaries and
relayed them by e-mail to the data center during the JCP season.
Data were collected and analyzed after the JCP season.
Cry j1-galactomannan conjugates
Standardized JCP antigen-galactomannan conjugates were
manufactured by Wako Filter Technology Co., Ltd. (Ibaraki, Japan)
and were of Good Manufacturing Practice grade.21 A capsule of JCPFig. 2. Study design, daily Japanese cedar pollen counts and total symptom medication
(TSM) scores. Visit 1: early January 2012, screening of potentially eligible subjects. Visit
2: mid-February 2012, the beginning of JCP season approximately 2 weeks after the
beginning of the maintenance phase of OIT. Visit 3: middle of May 2012, the end of the
JCP season. Duration of OIT: early January to late March 2012. JCP season: mid-
February to late April 2012. Mean JCP counts in Fukuoka City, Japan, 2012, and TSM
scores. Solid line: JCP counts. Open squares: TSM score in the OIT group (n ¼ 23). Solid
squares: TSM score in the control group (n ¼ 24). **P < 0.01; ***P < 0.001, between the
OIT and control groups.antigenegalactomannan conjugate contained 187.5 mg of Cry j1,
which is the major allergen of JCP.
Pollen counts
The mean annual amount of cedar pollen in Fukuoka was
measured using Durham pollen samplers in two different areas:
Fukuoka City Medical Association Hospital and Fukuoka National
Hospital.
Adverse events
Adverse events (AEs) were monitored throughout OIT and were
graded according to the Common Terminology Criteria for Adverse
Event (CTCAE) v4.0. Brieﬂy, adverse events were graded as mild
(grade 1), moderate (grade 2), severe (grade 3), life-threatening
(grade 4), death (grade 5) according to the allergy/immunology
category in the CTCAE v4.0 scoring system. Discontinuation criteria
for OIT were grade 3 adverse events and even grade 2 adverse
events if the participant wished to withdraw from the study. The
occurrence of AEs with OIT was assessed as a secondary outcome.
Symptoms and medication use
During the cedar pollen season, participants recorded their
weekly symptoms of rhinoconjunctivitis, which were evaluated on
a scale from 0 to 4 in accordance with the Japanese Allergic Rhinitis
QOL Standard Questionnaire No. 1 (JRQLQ No 1).26 The total
symptom (TS) score was calculated as the sum of each component
score as follows: none, 0; mild, 1; moderate, 2; severe, 3; and very
severe, 4. Nasal and ocular symptoms covered by the questionnaire
included runny nose, sneezing, nasal congestion, itchy nose, itchy
eyes andwatery eyes. The total medication score everyweek during
the cedar pollen seasonwas also calculated and recorded according
to the drug type and duration of usage, based on the Practical
Guideline for the Management of Allergic Rhinitis in Japan25,26 as
follows. Antihistamines, leukotriene antagonists and topical ocular
antihistamines were listed as 1, topical nasal steroid sprays and
ocular steroid drops as 2, and oral corticosteroids as 3.
First, we treated participants using antihistamines or leuko-
triene antagonists as rescue medications for the relief of symptoms.
If symptoms were not improved and participants desired more
drugs, we prescribed nasal steroid sprays and/or ocular antihista-
mine drops according to symptoms in addition to the initial rescue
medication. Moreover, if symptoms were not improved and par-
ticipants desired more drugs, we prescribed topical ocular steroid
drops and/or oral corticosteroids. The total symptom medication
(TSM) score reﬂected the average total symptom score (which
comprised six types of scores, with 4 points for the maximumvalue
plus the total medication score). In the present study, the primary
outcome was the efﬁcacy of OIT using the Cry j1-galactomannan
conjugate for JCP that was assessed by examining the TSM score.
Analysis of allergen-speciﬁc serum antibodies
The levels of antigen-speciﬁc serum IgE and IgG4 were exam-
ined with Fluoro Enzyme Immunoassay (ImmunoCAP System,
Phadia, Uppsala, Sweden) according to the manufacturer's in-
structions. The level of allergen-speciﬁc serum antibodies was
assessed as a secondary outcome.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.
Comparisons between the control group and the OIT group at
Table 2
Adverse events (AEs) during oral immunotherapy (OIT) using the Cry j 1-
galactomannan conjugate.
No. M/F AEs Severity
(grade)
Days of
treatment
Duration
(days)
OIT group 1 M Nausea Grade 1 67 0.1
Diarrhea Grade 1 67 0.1
2 M Pruritusz Grade 1 11 7
3 M Nausea Grade 1 35 0.1
Vomiting Grade 1 35 0.1
Cough Grade 1 35 0.1
Laryngopharyngeal
dysesthesia
Grade 1 35 0.1
Urticaria Grade 2 35 0.1
4 M Rhinitis Grade 1 1 7
5 M Rhinitis Grade 1 10 5
Sneezing Grade 1 10 5
Nasal congestion Grade 1 10 5
6 M Malaise Grade 1 1 4
Diarrhea Grade 1 10 0.5
7y M Laryngopharyngeal
dysesthesia
Grade 1 1 7
Pruritusz Grade 1 51 1
Laryngopharyngeal
dysesthesia
Grade 1 51 1
Edema face Grade 1 51 1
Urticaria Grade 1 51 1
Pruritusz Grade 1 53 3
Urticaria Grade 1 53 1
Laryngopharyngeal
dysesthesia
Grade 1 53 3
Pruritusz Grade 1 68 1
Urticaria Grade 1 68 1
Laryngopharyngeal
dysesthesia
Grade 1 68 1
8 M Pruritusz Grade 1 11 28
9 F Pruritusz Grade 1 6 26
Rash maculopapular Grade 1 28 32
AEs were graded according to Common Terminology Criteria for Adverse Event
(CTCAE) v4.0. Total AEs (%): 9/23 (39.1%); build-up phase: 7/23 (30.4%), maintenance
phase: 4/23 (17.3%). M, male; F, female.
y Treatment-related withdrawal: 1/23 (4.3%).
z Pruritus on any part of the body.
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ManneWhitney U-test. Comparisons of paired samples from par-
ticipants before and at different time points during the pollen
season were performed using the Wilcoxon signed-rank test. Dif-
ferences were considered statistically signiﬁcant when P < 0.05.
Results
Patient characteristics
Fig. 1 describes the enrollment and characteristics of partici-
pants. Of 23 participants, 1 withdrew from OIT because of adverse
effects. None of the 23 participants undergoing OIT and none of 24
participants who did not undergo OIT withdrew from the study
during the pollen season. In the ITT analysis of primary outcome
and AEs, the 23 participants in the OIT group and the 24 partici-
pants in the control group fully complied with the study protocol.
The characteristics of each group are presented in Table 1. No dif-
ferences in baseline characteristics were observed.
Adverse effects
Of the 23 participants, 9 suffered from AEs during OIT as shown
in Table 2. During the build-up phase of OIT, 7 of 23 participants had
grade 1 AEs as determined by CTCAE v4.0. Only one of the seven
participants with AEs had diarrhea related to gastrointestinal dis-
orders but the symptom resolvedwithout any treatment. Three had
pruritus on the body and one of them was treated with an anti-
histamine cream while the others had no treatment. Pruritus
resolved in all patients either after 1 week or 1month following the
beginning of the build-up phase. Two of seven participants had
rhinitis similar to pollinosis with or without sneezing and nasal
congestion. One of them received an oral antihistamine for a few
days while the others had no treatment. The symptoms including
sneezing and nasal congestion resolved after about 1 week. In one
of the seven participants, malaise and laryngopharyngeal dyses-
thesia occurred immediately after immunotherapy but resolved
within a week without any treatment. During the maintenance
phase of OIT, 4 of 23 participants suffered from new AEs. Two of the
four participants with AEs had grade 1 diarrhea and nausea/Table 1
Participant demographics.
Group OIT Control P value
Number 23 24
Sex (M/F) 14/9 13/11 0.432
Mean age 38.6 ± 11.2 33.7 ± 9.2 0.107
Range 25e60 22e58
Total IgE [IU/ml] 426 ± 1413 174 ± 191 0.685
Range 13e6870 11e850
Cry j1-Speciﬁc IgE [UA/ml] 10.6 ± 10.6 22.6 ± 24.2 0.054
Range 1.43e46.1 2.11e92.2
Other allergies (%)
House dust mite 7 (30.4%) 12 (50%) 0.142
Asthma 1 (4.3%) 0 (10%) 0.489
Atopic dermatitis 4 (17.3%) 3 (12.5%) 0.475
Food allergy 3 (13.0%) 5 (20.8%) 0.375
Symptom score of pre-pollen season
Total symptom score 2.1 ± 2.9 3.0 ± 2.4 0.134
Total nasal symptom score 1.6 ± 2.1 2.4 ± 1.9 0.095
Total ocular symptom score 0.5 ± 0.8 0.5 ± 1.0 0.746
Results of the intention-to-treat (ITT) group in percentages, ranges or means ± SDs.
Total symptom (TS) score includes total nasal symptom score (sneezing, itchy nose,
nasal congestion) and total ocular symptom score (watery eyes and itchy eyes).
Total score ¼ total of 6 individual symptom scores, each assessed on a 5-point scale
(from 0 ¼ absent to 4 ¼ very severe). Statistical analysis was performed using the
ManneWhitney U-test or Fisher's exact probability test. M, male; F, female.vomiting related to gastrointestinal disorders. One of them with
grade 1 vomiting also had grade 1 cough, laryngopharyngeal dys-
esthesia and grade 2 urticaria. The symptoms appeared about one
hour after taking the oral capsules, and the participant visited the
hospital immediately and was treated with intravenous antihista-
mines and steroids. The symptoms resolved a few hours after
treatment. OIT was restarted at half the maintenance dose and the
maintenance dose was reached in 12 days. After that, OIT could be
administered without any further AEs. The other participant
recovered without treatment a few hours after the appearance of
symptoms. Furthermore, one of the four participants with AEs had
a grade 1 maculopapular rash but it resolved within a month
without any treatment. Only one of the four participants with AEs
during the maintenance phase ceased OIT because of recurrent
grade 1 urticaria on the face, pruritus and laryngopharyngeal dys-
esthesia on days 51, 53, and 68 during OIT, although the symptoms
resolved on the next day or after a few days without treatment. It
was possible for this participant to continue OIT but he chose to
discontinue OIT near the end of therapy because of recurrent grade
1 AEs.
Pollen counts
In 2012, the Japanese cedar pollen season started in late
February and ended at the beginning of April in Fukuoka City, Japan
(Fig. 2). The mean annual amount of cedar pollen was 1368/cm2 in
Fukuoka.
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Clinical efﬁcacy was based on weekly symptom and medication
scores. TSM score and pollen counts in the community during the
JCP season are shown in Fig. 2. The temporal proﬁles of TSM scores
were lower in the OIT group compared with the control group at all
six time points from 26 February to 1 April, 2012, during the JCP
season (P values for the time points in chronological order: P values
of 0.006, <0.001, <0.001, <0.001, <0.001 and <0.001). The mean
scores for the symptoms of sneezing, itchy nose, itchy eyes, the total
nasal symptom score, the total ocular symptom score, TS score,
medication score and TSM scores were also lower in the OIT group
comparedwith the control group during the JCP season as shown in
Fig. 3AeD (P values of 0.006, 0.004, 0.013, 0.015, 0.009, 0.010,
<0.001 and <0.001, respectively).
Allergen-speciﬁc serum antibodies
To objectively determine the effects of OIT, we evaluated the
levels of serum antibodies including allergen-speciﬁc serum anti-
bodies in the OIT and control groups. Fig. 4A shows the change inFig. 3. Symptoms and medication use. A, Symptom scores. B, Total nasal and ocular sympto
OIT group (n ¼ 23); solid square: control group (n ¼ 24). Each score represents the meanwee
box-and-whisker plots. *P < 0.05; **P < 0.01; ***P < 0.001, between the OIT and control grthe serum levels of total IgE, total IgG, Cry j1-speciﬁc IgE and Cry
j1-speciﬁc IgG4 in the OITand control groups during the JCP season.
The levels of total IgE and IgG in the OIT group remained the same
through the JCP season from visit 1 before the JCP season to visit 3
after the JCP season. However, the levels of total IgE and total IgG
decreased in the control group at visit 2 (the beginning of the JCP
season) compared with those at visit 1 (P ¼ 0.028 and 0.001,
respectively). Levels remained the same at visit 3. The levels of Cry
j1-speciﬁc IgE and IgG4 increased in the OIT group at visit 2 (the
beginning of the JCP season and the maintenance phase of OIT)
compared with those at visit 1 (P ¼ 0.005 and 0.006, respectively).
Furthermore, the level of Cry j1-speciﬁc IgE increased at visit 3 after
the JCP season compared with that at visit 2 (P < 0.001). The level of
Cry j1-speciﬁc IgG4 remained the same at visit 3. However, the
levels of Cry j1-speciﬁc IgE and IgG4 at visit 2 remained the same
compared with those at visit 1 and were increased at visit 3 in the
control group (P < 0.001 and <0.001, respectively). Thus, the
elevated levels of Cry j1-speciﬁc IgE and IgG4 during OIT at visit 2 of
the JCP season compared with visit 1 before the JCP season show
that an antigen-speciﬁc immune response was induced by the Cry
j1-galactomannan conjugate. However, there was no signiﬁcantm scores and total symptom scores. C, Medication score. D, TSM scores. Open squares:
kly score during peak pollen season (23 February to 1 April, 2012). Data are depicted as
oups.
Fig. 4. Measurement of serum total IgE and IgG, and Cry j1-speciﬁc IgE and IgG4. A, Changes in individual serum total IgE and IgG, and Cry j1-speciﬁc IgE and IgG4. Open squares:
OIT group; solid squares: control group. V1: OIT group (n ¼ 23); control group (n ¼ 24), V2: OIT group (n ¼ 23); control group (n ¼ 24), V3: OIT group (n ¼ 21); control group
(n ¼ 24). *P < 0.05; **P < 0.01; ***P < 0.001, between each visit in individuals. B, Group comparisons of serum immunoglobulins. Open squares: OIT group; solid squares: control
group. Data are depicted as box-and-whisker plots. V1: OIT group (n ¼ 23); control group (n ¼ 24), V2: OIT group (n ¼ 23); control group (n ¼ 24), V3: OIT group (n ¼ 21); control
group (n ¼ 24).
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and Cry j1-speciﬁc IgG4 in serum samples collected before JCP
season and OIT (visit 1), at the beginning of JCP season (visit 2), and
after JCP season (visit 3) between the OIT and control groups as
shown in Fig. 4B.
Discussion
OIT is in the spotlight again as an effective treatment for food
allergy including cow's milk, peanuts, eggs, etc.16e18 In addition, we
recently reported for the ﬁrst time that short-term OIT for only one
monthbefore thepeakpollenseasonusing theCry j1-galactomannan
conjugate for JCP is effective and relatively safe.23 However, the
optimum regimen of OIT using the Cry j1-galactomannan conjugate
has not been established. In this study, we show that a new regimen
of short-term OIT using the Cry j1-galactomannan conjugate with a
build-up phase and a maintenance phase that extends to the peak
pollen season is effective, relatively safe, and can induce immune
tolerance in participants who are sensitized to the JCP allergen.
In our recent study, we showed that the TS score and the TSM
score were signiﬁcantly improved in the OIT group during the peak
pollen season.23 However, the medication score was not improved
because it was lower in the OIT group than in the control group at
the beginning of the pollen season, and it was the same in the late
period of the pollen season. Therefore, the TSM score was not
improved signiﬁcantly in the OIT group compared with the control
group in the late period of the pollen season. These results raise the
possibility that tolerance induced by OIT cannot be maintained
throughout the pollen season. We thus hypothesized that OIT
through the peak pollen season in addition to OIT before the pollen
season, such as the regimens of SCIT and SLIT, might enhance the
therapeutic effect of OIT. In this study, the medication score was
signiﬁcantly improved in the OIT group throughout the peak pollen
season, and the medication score was also signiﬁcantly improved
even in the late period of the pollen season in the OIT group. In
addition, compared with the control group, the OIT group showed
signiﬁcant improvements in the TS score and TSM score, which
represent the primary endpoint, during the peak pollen season. On
the other hand, a signiﬁcant difference in each symptom score
including runny nose, nasal congestion and watery eyes was not
observed. Generally, the severity of symptoms including nasal
discharge and nasal obstruction increases with greater amounts of
cedar pollen. The annual amount of cedar pollen in 2012 around
Fukuoka city was less than the annual average of 1888/cm2 in the
last decade.27 Thus, each symptom score in the control group in
2012 was relatively small compared with those in our previous
study of the 2011 season that had a large annual amount of cedar
pollen (2621/cm2),23 which was not a direct comparison. The small
annual amount of cedar pollen in 2012 may contribute to the small
difference of each symptom score between the control and OIT
groups and make it more difﬁcult to detect a difference in each
symptom score.
Furthermore, although the maintenance phase of OIT was
extended to the late period of the pollen season, it did not affect
compliance because all participants found the regimen acceptable
and completed the OIT, except for one person who withdrew
because of AEs. In the standard regimen of both SLIT and SCID for
cedar pollinosis, it is necessary to start the immunotherapy more
than six months before the pollen season and continue the
immunotherapy for a few years before the effectiveness of the
treatment can be determined.6 The period of immunotherapy is
long and this has been a major disadvantage for patients, especially
those who do not beneﬁt from immunotherapy. In contrast, OIT in
this study started from one month before the pollen season and
continued for about two months until the late period of the pollenseason, which is very short compared with the standard regimen of
both SLIT and SCID. This length of treatment is the same as that of
conventional drug therapy for JCP. Thus, good compliance is ex-
pected for this OIT regimen.Moreover, patients can choosewhether
to continue the immunotherapy next year because its efﬁcacy is
known after one course of treatment in a single pollen season. It
also beneﬁts patients who do not experience the therapeutic effect
of immunotherapy.
The new regimen of prolonged OIT for about two months in this
study showed therapeutic efﬁcacy throughout the pollen season
and there was good compliance. Thus, we think it is a reasonable
and convenientmethod but the cost of therapy is increased. Further
study of the efﬁcacy and method of administration is required to
reduce costs (for example, administration every other day).
The safety of OIT for pollen allergy has been conﬁrmed in many
trials, and no severe systemic side effects were reported. However,
many minor side effects (not life-threatening) were observed
because the native form of the allergen was administered for OIT.12
These effects tended to increase with an increased dosage of
allergen.13 It is therefore desirable to develop a new agent to sup-
press gastrointestinal AEs associated with OIT. In a recent study, we
reported that short-term OIT using the Cry j1-galactomannan
conjugate for JCP was relatively safe.23 Although the OIT regimen
did not have a build-up phase, only 7 of 23 participants who un-
derwent OIT had mild (grade 1) or moderate (grade 2) AEs (5 had
mild and 2 had moderate AEs), and only 2 of 7 participants with
adverse events developed mild gastrointestinal disorders. No se-
vere AEs were occurred.
In previous studies of OIT for food allergy, AEs were more
frequent with initial day dose escalation and in the build-up phase.
The rates of AEs were the highest during the early period of oral
immunotherapy.17,18 In addition, the risk of anaphylaxis was highest
with rushprotocols andoverdose.28 These observations suggest that
a build-up phase in theOIT regimenusing theCry j1-galactomannan
conjugate is necessary to enhance therapeutic safety.
In this study, 7 of 23 OIT participants had mild (grade 1) AEs
during the build-up phase. During themaintenance phase, the rates
of AEs were decreased compared with the build-up phase. Only 4 of
23 participants had new adverse effects. Three of four participants
with AEs had mild (grade 1) AEs and one had moderate (grade 2)
AEs. No severe AEs occurred in both the build-up phase and the
maintenance phase. Furthermore, the rate of AEs in the mainte-
nance phase decreased relative to that in the build-up phase, which
was similar to the phenomenon in previous studies of OIT17,18 and
this shows that the new regimen of OIT with a build-up phase is
safe compared with the regimen without a build-up phase. With
respect to the duration and dose escalation in the build-up phase,
further research is needed to improve the safety of this regimen.
To demonstrate objective evidence for the in vivo effect of OIT
using the Cry j1-galactomannan conjugate, we investigated the
levels of serum Cry j1-speciﬁc antibodies. The levels of serum Cry
j1-speciﬁc IgE and IgG4 during OIT were signiﬁcantly increased in
the OIT group but not in the control group at the beginning of the
cedar pollen season (Visit 2). This result shows that the antigen-
speciﬁc immune response for cedar pollen antigen arose in vivo
during OIT using the Cry j1-galactomannan conjugate. The change
in serum Cry j1-speciﬁc IgG4 and IgE levels during the pollen
season is very similar to previous studies of OIT for birch pollen
allergy11 and peanut allergy.17 Moreover, the increased level of
serum Cry j1-speciﬁc IgG4 in the OIT group throughout the cedar
pollen season suggest that OIT with the Cry j1-galactomannan
conjugate is also an effective treatment that is comparable to SLIT
and SCIT.29
There are some limitations in our study: the study cohort was
small; the studydidnotuseaplaceboarm;and the trialwasanopen-
D. Murakami et al. / Allergology International 64 (2015) 161e168168label study. Further research is required todeterminewhether anew
regimen of OIT using the antigenegalactomannan conjugate is a
universally effective method for the treatment of airway allergy.
In summary, we reported that the new regimen of short-term
OIT using the Cry j 1-galactomannan conjugate is effective, rela-
tively safe, and can induce antigen-speciﬁc immune responses. Our
ﬁndings suggest that OIT using allergenegalactomannan conju-
gates permits a shorter, effective, and thus convenient immuno-
therapy regimen for cedar pollinosis compared with SLIT or SCIT
that takes a few years before the therapeutic effect is apparent.
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